Company intelligence / Profile preview

ABIGO Medical

Ownership: Private
Employees: ~160
Development stage: Other

Overview

Sorbact® technology has been proven in more than 40 clinical studies involving over 7,000 patients. It is used globally for advanced wound care to prevent and treat infections by binding bacteria and fungi without antiseptics or toxic substances. The product line is commercialized in over 65 countries with strong clinical evidence supporting efficacy and safety.

Therapeutic areas: Infectious DiseasesOther
Modalities: DeviceNon-pharmacological therapy
Industry: Consumable Medical Devices

Partnerships

Essity was a key partner before acquisition; now parent company.Distribution partners worldwide.

Beyond the preview

Go deeper on ABIGO Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABIGO Medical.

Explore the full profile